Supplementary Table 7 from Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib

Ida H.; Shimizu T.; Nishino M.; Nakamura Y.; Yazaki S.; Katsuya Y.; Sato J.; Koyama T.; Iwasa S.; Sudo K.; Kondo S.; Yonemori K.; Shitara K.; Shiono S.; Matsuoka D.; Yasuda K.; Otake Y.; Suzuki T.; Takase T.; Takashima S.; Yamaguchi K.; Semba T.; Yamamoto N.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Supplementary Table 7 from Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib

Ida H., Shimizu T., Nishino M., Nakamura Y., Yazaki S., Katsuya Y., Sato J., Koyama T., Iwasa S., Sudo K., Kondo S., Yonemori K., Shitara K., Shiono S., Matsuoka D., Yasuda K., Otake Y., Suzuki T., Takase T., Takashima S., Yamaguchi K., Semba T., Yamamoto N.

<p>Supplementary Table 7. Tumor Biomarkers: Assessment of Immune Phenotypes</p>

Original publication

DOI

10.1158/2767-9764.23654035.v1

Type

Other

Publication Date

10/07/2023